Publication. Either party, consistent with academic standards, may publish or present the Data (as defined in Article 8 below), provided such publication or presentation does not disclose the other party’s Confidential Information. The Parties agree that any publication or presentation of Data shall appropriately cite the contributions of both Parties, using customary standards of scientific attribution. Each Party shall provide the other Party with a copy of such publication or presentation ​ prior to submission for presentation or publication to permit protection of any Confidential Information and/or patent rights, if desired and applicable. The other Party shall have ​, after receipt of said copies, to object to such proposed presentation or proposed publication because it includes patentable subject matter which needs protection or because it includes Confidential Information of such other Party. In the event that the other Party makes such objection, the publishing party shall refrain from making such publication or presentation for a maximum of ​ from date of receipt of such objection in order to allow the other Party to seek patent protection on any patentable Inventions included in the proposed publication or presentation, and the publishing Party shall remove the other Party’s Confidential Information from such publication or presentation before submitting or presenting it to any Third Party. Atara further agrees that Institute shall have the first right to publish any results of the Research Collaboration, pursuant to the terms of this Article 7. In the case of Confidential Information of Atara being results of the Research Collaboration, Institute may publish a publication or presentation containing such information after taking into account any comments by Atara in good faith and after allowing Atara to seek patent protection in accordance with this Section 7.1, unless Atara (acting reasonably) designates such information as a ‘Trade Secret’.

Scientific Publication. Each Party shall have the right to make publications in accordance with this Section 10.4; provided that any publication by Beam that relates to Licensed Products and is not primarily directed to Beam Platform Technology shall be subject to Sana’s prior written consent (which may be withheld or denied in its sole discretion). Consequently, either Party or its Affiliates shall deliver to the other Party for review and comment a copy of any scientific proposed publication or presentation of technology that describes or contains the other Party’s Confidential Information, at least ​ days prior to the date of disclosure. During such ​ day period, the reviewing Party shall have the right to require modifications of the publication or presentation: # to protect the Parties’ Confidential Information; # for trade secret reasons or reasonable business reasons; and/or # to delay such submission for an additional period up to ​ days as may be reasonably necessary to seek patent protection for the information disclosed in such proposed submission. The Parties shall comply with traditional standards of authorship with respect to scientific publications.

Scientific Publication. Except to the extent required by Applicable Laws, Ji Xing shall not publish any peer-reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, relating to the Product, including the data and results of the Development of the Product, without [[Cytokinetics:Organization]]’ review and approval, which approval shall not be unreasonably withheld, delayed or conditioned. Ji Xing shall deliver to [[Cytokinetics:Organization]] for review and approval a copy in English of any proposed scientific publication or presentation relating to the Product at least ​ before its intended submission for publication. [[Cytokinetics:Organization]] shall have the right to require modifications of the proposed publication or presentation to protect [[Cytokinetics:Organization]]’ Confidential Information and for trade secret reasons ​. [[Cytokinetics:Organization]] may also delay the submission of the proposed publication or presentation for an additional ​ as may be reasonably necessary to seek patent protection for the information disclosed in such proposed publication or presentation. Ji Xing agrees to acknowledge the contribution of [[Cytokinetics:Organization]] and [[Cytokinetics:Organization]]’ employees in all publication as scientifically appropriate.

Scientific Publication. Each Party and its Affiliates shall have the right to make disclosures pertaining to Products to Third Parties in publications in accordance with the following procedure: the publishing Party shall provide the non-publishing Party with an advance copy of the proposed publication at least ​ prior to submission for any publication, and the non-publishing Party may review and comment on the proposed publication, which the publishing Party shall consider in good faith. In addition, if the non-publishing Party informs the publishing Party that such proposed publication contains the Know-How or Confidential Information of the non-publishing Party, the publishing Party shall delay or prevent such publication as follows: # with respect to a patentable invention, such publication shall be delayed sufficiently long (not to exceed ​) to permit the timely preparation and filing of a patent application; and # with respect to Confidential Information of such non-publishing Party, such Confidential Information shall be deleted from the publication.

Scientific Publication. The JSC shall discuss the publication strategy for the publication of scientific papers, abstracts, meeting presentations and other disclosure of the results of the Clinical Trials carried out under this Agreement, taking into consideration the Parties’ interest in publishing the results of the Product Development work in order to obtain recognition within the scientific community and to advance the state of scientific knowledge, and the need to protect Confidential Information, intellectual property rights and other business interests of the Parties. Subject to the immediately preceding sentence, Zai shall provide TPTX with the opportunity to review and comment on any proposed publication that pertains to the Products at least ​ days prior to its intended submission for publication which shall only be permitted in the Territory and as to data, results and the like with respect to patients or subjects located in the Territory. TPTX shall provide Zai with its comments, if any, within ​ days after the receipt of such proposed publication. Zai shall consider in good faith the comments provided by TPTX and shall comply with TPTX’s request to: # remove any and all Confidential Information of TPTX from such proposed publication; and # delay the submission for a period up to ​ days as may be reasonably necessary to seek patent protection for the information disclosed in the proposed publication. Zai agrees to acknowledge the 92975109_3

Publication. For purposes of this [Section 13.4], the terms “publish” and “scientific presentation” (including variations such as “publication” and “presentation”) shall mean any public disclosure in the nature of a published paper, article, manuscript, report, poster, internet posting, presentation slides, abstract, outline, video, instructional material, presentation, or the like, in printed, electronic, or oral form.

Scientific Publication. Xenon shall not publish or otherwise publicly disclose any results of studies carried out under this Agreement or prior to the Effective Date related to the Compounds or Products without the prior written approval of Neurocrine, which Neurocrine may grant or withhold in its sole discretion, unless such information has already been publicly disclosed in the same format either prior to the Effective Date or after the Effective Date through no fault of Xenon and otherwise not in violation of this Agreement and remains accurate at the time of re-publication, and except for the publications listed on Exhibit R. Nothing in this Agreement will restrict, or be deemed to restrict, Neurocrine from publishing the results of any studies conducted hereunder related to Compounds or Products.

Scientific Publication. Scientific publication strategy shall be managed by the JSC, which shall consider Sangamo’s and Kite’s interest in publishing the results of its research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge, the need to protect Confidential Information and the Parties’ mutual interest in obtaining valid patent protection, protecting reasonable business interests and trade secret information and having an integrated approach to permit Kite to develop one or more Licensed Products in the Field. Each Party shall have the right to make publications in accordance with this [Section 11.4]; provided that any publication by ​ of any results obtained under this Agreement shall be subject to ​ prior written consent, such consent not to be unreasonably withheld. Either Party or its Affiliates shall deliver to the other Party for review and comment a copy of any scientific proposed publication or presentation that pertains to the Licensed Product(s), pursuant ​ = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Scientific Publication. Except to the extent required by Applicable Laws, Ji Xing shall not publish any peer-reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, relating to the Product, including the data and results of the Development of the Product, without [[Cytokinetics:Organization]]’ review and approval, which approval shall not be unreasonably withheld, delayed or conditioned. Ji Xing shall deliver to [[Cytokinetics:Organization]] for review and approval a copy in English of any proposed scientific publication or presentation relating to the Product at least ​ before its intended submission for publication. [[Cytokinetics:Organization]] shall have the right to require modifications of the proposed publication or presentation to protect [[Cytokinetics:Organization]]’ Confidential Information and for trade secret reasons ​. [[Cytokinetics:Organization]] may also delay the submission of the proposed publication or presentation for an additional ​ as may be reasonably necessary to seek patent protection for the information disclosed in such proposed publication or presentation. Ji Xing agrees to acknowledge the contribution of [[Cytokinetics:Organization]] and [[Cytokinetics:Organization]]’ employees in all publication as scientifically appropriate.

Publication. Either party, consistent with academic standards, may publish or present the Data (as defined in Article 8 below), provided such publication or presentation does not disclose the other party’s Confidential Information. The Parties agree that any publication or presentation of Data shall appropriately cite the contributions of both Parties, using customary standards of scientific attribution. Each Party shall provide the other Party with a copy of such publication or presentation [ * ] prior to submission for presentation or publication to permit protection of any Confidential Information and/or patent rights, if desired and applicable. The other Party shall have [ * ], after receipt of said copies, to object to such proposed presentation or proposed publication because it includes patentable subject matter which needs protection or because it includes Confidential Information of such other Party. In the event that the other Party makes such objection, the publishing party shall refrain from making such publication or presentation for a maximum of [ * ] from date of receipt of such objection in order to allow the other Party to seek patent protection on any patentable Inventions included in the proposed publication or presentation, and the publishing Party shall remove the other Party’s Confidential Information from such publication or presentation before submitting or presenting it to any Third Party. Atara further agrees that Institute shall have the first right to publish any results of the Research Collaboration, pursuant to the terms of this Article 7. In the case of Confidential Information of Atara being results of the Research Collaboration, Institute may publish a publication or presentation containing such information after taking into account any comments by Atara in good faith and after allowing Atara to seek patent protection in accordance with this Section 7.1, unless Atara (acting reasonably) designates such information as a ‘Trade Secret’.